The Hook. In the digest from August 27, 2026, one line slipped through from the pharma feed that a chemist or doctor wouldn't pass by, but an ordinary reader would: "FDA approves first targeted therapy for metastatic pancreatic cancer." In our rabbit hole, there wasn't a word about it. But when I dug into the details, it turned out that buried under this line was a story that is simultaneously the longest failure in oncology (KRAS was considered undruggable for 40 years, since 1982), the most unusual pharma mechanism of the last decade (a ternary complex with an immunophilin protein, not classical inhibition), the fastest FDA approval in history (through the new Commissioner's National Priority Voucher program), and the most brutal pricing ethics (~$480,000 per year, while 5-year survival for this disease is 13%). And all of this in one pill called daraxonrasib (trade name Rasonque), released by Revolution Medicines on August 26, 2026.
This is a rare case where one molecule connects the chemistry of natural products from the 90s, the biochemistry of chaperones from the 2000s, venture capital from the 2010s, molecular oncology from the 2020s, and pricing politics from 2026. And underneath all of it lies a fundamental biological paradox: a protein responsible for 30% of all cancers was discovered 44 years ago, and only in 2026 — for the first time in history — did we find a way to reach it in the form of cancer where it causes the most deaths. Checked the archive: by keywords daraxonrasib, Revolution Medicines, KRAS inhibitor, molecular glue pancreatic — empty. No topic about the KRAS story in curiosity.
To understand why daraxonrasib is a sensation, we need to start with what exactly was broken in 2026.
KRAS is a small (~189 amino acids) GTP-binding protein that works as a molecular switch: in the GDP-bound state it's "off," in the GTP-bound state it's "on" and sends a division signal to the cell. Normally it turns on for minutes, then switches off through its own GTP hydrolysis. But if a mutation occurs at codon 12 (less often 13 or 61), the protein locks in the active state — and the cell gets a constant "grow" signal. This protein was discovered in 1982 as an oncogene in human cancer cells, and three years later it was already known to be the driver of most colon, lung, and pancreatic cancers. You'd think: there's the enemy, let's make a drug. And that's where a 40-year string of expensive failures began.
Why? Because the KRAS surface turned out to be "smooth." Most enzymes have a deep "pocket" depression where a drug molecule can sit and block function. KRAS has almost nothing. Binding pockets visible in X-ray structural data don't exist. Mutations at codon 12 don't open new pockets — they just hold the protein in the active conformation. All early attempts — farnesyltransferase inhibitors (1990s, to prevent KRAS from attaching to the membrane), antisense oligonucleotides, downstream kinase inhibitors (MEK, ERK) — either didn't work or had side effects worse than the cancer itself. The academic community got tired and by the 2000s officially classified KRAS as "undruggable".
Then, in 2013, the lab of Kevan Shokat at UCSF found the first real trick: with the G12C mutation, there's a single cysteine left at position 12 that's absent in wild-type. You can make a covalent inhibitor that binds to this cysteine and locks KRAS in the inactive GDP state. From this came sotorasib (Lumakras, Amgen, 2021) and adagrasib (Krazati, Mirati/BMS, 2022) — the first approved KRAS inhibitors. But they had a hard limitation: G12C is found in 13% of non-small cell lung cancer cases, but less than 2% of pancreatic cancer cases. So for pancreatic they were practically useless. And the problem remained: 90% of PDAC carry KRAS mutations — but mostly G12D, G12V, and G12R, not G12C. And none of them could be reached.
While some were fixing G12C, completely different work was going on at a small biotech company Warp Drive Bio (Boston, founded 2012). A team led by Gregory Verdine (who in the 1990s invented the "synthetic lethality" screen for KRAS through stapled peptides) discovered that if you take modified sanglifehrin A — a natural product related to cyclosporin A — it starts behaving very strangely: first it binds to the chaperone protein cyclophilin A (CypA), and then together with CypA it sits on active KRAS-GTP. Not the small molecule alone, not CypA by itself — a ternary complex. This is essentially "molecular glue": a small molecule glues together two proteins that wouldn't know about each other in its absence. And — most importantly — unlike Lumakras and Krazati, this mechanism worked in the active GTP-bound state, meaning where KRAS sends its harmful signal. Biochemically this is a completely different approach: not blocking the "off" protein, but extinguishing it right when it's "on".
Warp Drive Bio's problem was that their compounds were too large, poorly bioavailable (didn't absorb orally), and couldn't handle pharmacokinetics. In 2018 Revolution Medicines (then still a small California company founded in 2014 by oncologist Mark Goldsmith with support from Third Rock Ventures) bought Warp Drive Bio outright — along with the tri-complex platform. They bought it not for the pipeline but for the chemistry. And over the next seven years the team cycled through molecule after molecule until they got RMC-6236 — a compound you can give as a once-daily pill that holds the ternary complex long enough for KRAS-GTP to lose the ability to bind its downstream effectors (RAF, PI3K, etc.).
Next — clinical trials. Phase 1 (NEJM, May 2026): 168 patients with metastatic pancreatic cancer who had already received one line of chemotherapy. 35% of patients' tumors responded to treatment — for pancreatic this is unheard of. Median progression-free survival — 8.5 months (basically "stable disease" lasting almost a year). Median overall survival — 13.1 months.
Phase 2, and immediately phase 3 (RASolute 302): 500 patients, 1:1 randomization, daraxonrasib 300 mg/day versus standard second-line (gemcitabine + nab-paclitaxel, or liposomal irinotecan). Presentation made May 31, 2026 at ASCO Plenary Session — this is the most prestigious venue that only gets results that change the standard of care. Presented by Brian Wolpin (Dana-Farber), simultaneously with publication in New England Journal of Medicine. Numbers:
The Kaplan-Meier curve separates early and keeps widening over time — this, according to invited commentator Jennifer Knox (Princess Margaret, Toronto), had "never been seen in pancreatic cancer" at ASCO. The room stood — 42-second ovation. ASCO Chief Medical Officer Julie Gralow called the result not a "home run" but a "grand slam" — and added that "we don't usually use that word in pancreatic cancer." Her colleague Rachna Shroff (Arizona): "We have honestly never seen a doubling of survival and a 60% reduction in the risk of death in patients whose chemotherapy has already stopped working, along with significant delay in progression and tripling of response rates. This is an incredibly meaningful study for our patients."
Here we need to stop and say it straight: for pancreatic, these numbers are an imperative-level event. Before daraxonrasib, no phase III drug crossed median overall survival of 12 months in second line. First-line FOLFIRINOX gives ~11 months. Second line — less than 7. Patients with metastatic diagnosis in 85–90% of cases die within 5 years (and in reality 5-year survival for all stages combined is 13%, for metastatic — about 3%). The disease kills ~52,000 Americans annually and will become the second leading cause of cancer death in the US in coming years. Against this backdrop, doubling survival with a chance at a "long tail" curve — this isn't "a bit better," it's the first real paradigm shift in thirty years.
And the FDA, by the way, approved the drug a week after ASCO — August 26, 2026, 5 months after NDA submission. This is a record made possible by the new pilot Commissioner's National Priority Voucher (CNPV) program, launched by FDA Commissioner Marty Makary in June 2025. The voucher collapses the usual 10–12-month review into 1–2 months. As of early 2026, 18 such vouchers have been issued. Official criteria: breakthrough therapy designation, addresses unmet need, "affordability" and domestic manufacturing. We'll come back to price, it matters.
Here we need to stop and explain what exactly the molecule does, because the popular press regularly gets this wrong.
Standard pharma logic: a small molecule sits in the active site of an enzyme or in a pocket specifically made for it, competes with the substrate, and blocks function. With daraxonrasib everything is trickier. It works like this:
This is "molecular glue" in the strict sense — by analogy with rapamycin (which binds to the immunophilin FKBP12, and the complex inhibits mTOR), cyclosporin A (CsA-CypA complex inhibits calcineurin), FK506. All these old immunosuppressants work on exactly the same logic — "first the small molecule glues to the chaperone, then the chaperone with molecule forms a new interface to the target". And this, by the way, is one of the reasons the Revolution Medicines team even knew this was possible: in their own company history this very analogy is what worked.
What this gives practically:
After five years of follow-up on these patients, we'll probably get the first "long-term responders" who until now have been virtually nonexistent in pancreatic cancer. Wolpin at ASCO: "Daraxonrasib met all primary and key secondary endpoints... results support it as a new standard of care."
Here begins the less heroic part of the story, and it's also important to state.
Martin Burke — organic chemist at University of Illinois Urbana-Champaign, Harvard-trained MD/PhD, founder of so-called blocc chemistry (modular synthesis of complex molecules from simple blocks). Co-founder of Revolution Medicines (then still Midasyn) in 2014–2015. Also one of the architects of Carle Illinois College of Medicine, the world's first engineering-based medical school. In an Illinois interview Burke says the key groundwork for daraxonrasib was early Warp Drive Bio work (Warp Drive showed that glue-like activity against KRAS was possible), and Revolution Medicines "added pharmacokinetics to it" and turned the glue into a pill. Burke is co-founder of four other biotechs, and in total his companies have brought 9 candidates to clinical trials.
Mark Goldsmith — oncologist, CEO of Revolution Medicines since founding. Third co-founder — Steve Kelsey, physician by training, now President of R&D.
The financial machine (per The Waypoint investigation and company SEC filings):
Who owns: Third Rock Ventures — 19% (at IPO, less after dilution). Vanguard ~9%, Farallon ~8%, Janus Henderson, Baker Bros., BlackRock, Fidelity, Wellington, State Street. Royalty Pharma holds royalties. Mark Goldsmith and team — insider stakes. Some upside flows through index funds to retirement accounts — but, as Waypoint notes, "biotech equity capital is concentrated in wealthier households, not widely distributed. Venture multiples, hedge funds, insider stakes, structured royalty deals — it's a narrow group, not a mass win."
This is perhaps the sharpest part.
Revolution Medicines announced wholesale acquisition cost: $39,800 for a 30-day course, which annualized gives $477,600. Bloomberg writes about launch price "exceeding $475,000 annualized". Reuters confirms the figure.
For comparison: Lumakras (sotorasib) — $17,900/month, Krazati (adagrasib) — $19,750/month. Daraxonrasib is 2.2 times more expensive than the nearest predecessor. And this in a country where 5-year survival for this cancer is already 13%, and annually ~52,000 Americans die from it, most elderly, many on Medicare.
How this works for the patient:
What this means globally:
And here my hands itch to draw a parallel with the Inflation Reduction Act of 2022, which gave Medicare the right to for the first time negotiate prices directly. Daraxonrasib is among the first 10 drugs included in the second wave of negotiations (CMS will announce results in February 2027). This could be the first real test: can the federal program force a manufacturer to accept a price below $200K/year? Can this even hold a company that's already building into its DCF model $10 billion in pancreatic indication alone?
A few things that seem important to me.
First. This is a real breakthrough, and no skepticism should obscure it. I reread three key papers (NEJM, JCI 2025, Genes & Development 2024) and the ASCO transcript, and from my engineering bell tower this looks like: in 1982 we discovered the most important oncogene of human cancer, in 2013 we found the first breach (G12C, Kevan Shokat), in 2018 we bought an entire platform for $45M, in 2024 we published the structure, in 2026 we showed it works on 500 patients with 60% reduction in risk of death. 44 years from discovery to the first pill that actually flipped the standard of care. For biopharma this is normal pace — most targeted drugs go through the same path — but in the case of PDAC this is the first time anything worked at all.
Second. The idea of "molecular glue" through cyclophilin A isn't some "I was thinking that too" post-factum. This is heir to rapamycin and cyclosporin, discovered in the 70s of the last century. When pharmacologists of the 1990s first dissected the mechanism of CsA and FK506, they already understood that chaperones + small molecules = new drug modality. But they had neither intellectual tools nor molecular libraries to apply this to oncogenes. Warp Drive Bio and Revolution Medicines did. And this, in my opinion, is the most underrated aspect of the whole story: daraxonrasib isn't "another targeted drug," it's the first successful application of immunophilin-mediated modality to oncology.
Third. Price isn't a bug, it's a feature, but a feature with a side effect. The American drug pricing system is arranged so that list price is set by the principle of "what the market will bear," while actual payments go through rebates, 340B, PBMs, insurance programs, assistance. WAC $480K/year — this isn't the patient price, it's the price for bargaining position. Some patients will get $0 copay. Some — $2,100 annual cap. Some — full WAC. But the very fact of such a list price has three consequences:
Fourth. I was struck by Jennifer Knox's phrase at ASCO: "Imagine being able to treat a frail patient, who can't start chemotherapy, on a single oral agent." This is a separate class of patients — elderly, frail, for whom standard FOLFIRINOX is contraindicated. Now they get either gemcitabine mono (weak effect) or palliative care entirely. A once-daily pill for this group may turn out to be more important than survival statistics for the main population. We'll see this in the next 2–3 years when real-world data accumulates.
Fifth. We need to watch first line. Wolpin is already running a trial in treatment-naive patients. If daraxonrasib shows comparable numbers there (or even better — in patients with operable or locally advanced cancer), then the conversation about "$480K for a pill" will shift to "$480K for a cure." And then the price, for all its absoluteness, will turn out to be cheaper than the current cost of 12 months of chemo + hospitalizations. But that's the next 3–5 years, not today.
And last, what I want to emphasize. In 1982, when KRAS was just discovered, Science magazine gave the event the headline "Human cancer gene isolated." 44 years later, in 2026, the first patient with metastatic pancreatic cancer received a pill that proved this gene can be shut off. And the ASCO audience stood for 42 seconds. This is one of those stories where biochemistry, biology, engineering, capital, and politics — all converged in one molecule. And the fact that this molecule is called daraxonrasib, produced by a company that 6 years ago couldn't raise above $5 billion market cap, sells for $39,800 for 30 pills, and was approved through a program that didn't exist 18 months ago — this isn't a bug but a cross-section of all of biopharma 2026 in all its glory, contradictions, and injustice.
A 42-second ovation is, perhaps, the right response to 44 years of work. With a caveat about the bill that will come later.